Select Publications
Journal articles
2019, 'Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial', Circulation, 140, pp. 739 - 750, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007
,2019, 'The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study', Quality of Life Research, 28, pp. 2081 - 2090, http://dx.doi.org/10.1007/s11136-019-02173-1
,2019, 'Benefits and harms of oral anticoagulant therapy in chronic kidney disease', Annals of Internal Medicine, 171, pp. 181 - 189, http://dx.doi.org/10.7326/M19-0087
,2019, 'Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study', BMC Nephrology, 20, pp. 258, http://dx.doi.org/10.1186/s12882-019-1438-3
,2019, 'Cardiovascular adaptations associated with exercise in patients on hemodialysis', Seminars in Dialysis, 32, pp. 361 - 367, http://dx.doi.org/10.1111/sdi.12789
,2019, 'Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial', Journal of Renal Nutrition, 29, pp. 276 - 284, http://dx.doi.org/10.1053/j.jrn.2018.10.009
,2019, 'Canagliflozin and renal outcomes in type 2 diabetes and nephropathy', New England Journal of Medicine, 380, pp. 2295 - 2306, http://dx.doi.org/10.1056/NEJMoa1811744
,2019, 'Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis', Nephrology, 24, pp. 605 - 614, http://dx.doi.org/10.1111/nep.13445
,2019, 'Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis', Diabetes, Obesity and Metabolism, 21, pp. 1237 - 1250, http://dx.doi.org/10.1111/dom.13648
,2019, 'Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials', BMC Cardiovascular Disorders, 19, pp. 87, http://dx.doi.org/10.1186/s12872-019-1054-y
,2019, 'Effect of extended hours dialysis on sleep quality in a randomized trial', Nephrology, 24, pp. 430 - 437, http://dx.doi.org/10.1111/nep.13236
,2019, 'Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study', PLoS ONE, 14, pp. e0213192, http://dx.doi.org/10.1371/journal.pone.0213192
,2019, 'Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction on Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study', BMJ Open, 9, pp. e024382, http://dx.doi.org/10.1136/bmjopen-2018-024382
,2019, 'Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018', Canadian Journal of Kidney Health and Disease, 6, http://dx.doi.org/10.1177/2054358119894394
,2019, 'Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program', Journal of the American Society of Nephrology, 30, pp. 2229 - 2242, http://dx.doi.org/10.1681/ASN.2019010064
,2019, 'Kidney Health Australia - Caring for Australasians with Renal Impairment guideline recommendations for infection control for haemodialysis units', Nephrology, 24, pp. 951 - 957, http://dx.doi.org/10.1111/nep.13511
,2019, 'Protocol for the Study of Heart and Renal Protection-Extended Review: Additional 5-Year Follow-up of the Australian, New Zealand, and Malaysian SHARP Cohort', Canadian Journal of Kidney Health and Disease, 6, pp. 2054358119879896, http://dx.doi.org/10.1177/2054358119879896
,2019, 'Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol', BMJ Open, 9, pp. bmjopen-2018-023736, http://dx.doi.org/10.1136/bmjopen-2018-023736
,2019, 'Abstract #259 Cardiovascular and Renal Outcomes with Canagliflozin in People with Type 2 Diabetes According to Baseline use of Metformin', Endocrine Practice, 25, pp. 99 - 100, http://dx.doi.org/10.1016/s1530-891x(20)46603-0
,2019, 'SAT-041 A META-ANALYSIS OF THE REPRESENTATIVENESS OF RANDOMIZED CONTROLLED TRIAL COHORTS IN END-STAGE KIDNEY DISEASE', Kidney International Reports, 4, pp. S21 - S21, http://dx.doi.org/10.1016/j.ekir.2019.05.064
,2019, 'SAT-241 SMALL AREA-LEVEL VARIATION IN CHRONIC KIDNEY DISEASE PREVALENCE AND INCIDENCE IN NEW SOUTH WALES', Kidney International Reports, 4, pp. S108 - S108, http://dx.doi.org/10.1016/j.ekir.2019.05.277
,2019, 'SAT-288 Trends in pharmacotherapy for diabetes in a large Australian cohort: results from the EXTEND45 study', Kidney International Reports, 4, pp. S128 - S129, http://dx.doi.org/10.1016/j.ekir.2019.05.326
,2019, 'SAT-289 Association between the intensity of diabetes pharmacotherapy regimens, persistence and achieved HbA1c in a large Australian cohort: results from the EXTEND45 study', Kidney International Reports, 4, pp. S129 - S129, http://dx.doi.org/10.1016/j.ekir.2019.05.327
,2019, 'SAT-298 EFFECT OF SGLT2 INHIBITORS ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE', Kidney International Reports, 4, pp. s133, http://dx.doi.org/10.1016/j.ekir.2019.05.338
,2018, 'Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop', Kidney International, 94, pp. 1053 - 1068, http://dx.doi.org/10.1016/j.kint.2018.08.018
,2018, 'Glucose lowering and the kidney: are all drug classes equal?', The Lancet Diabetes and Endocrinology, 6, pp. 835 - 837, http://dx.doi.org/10.1016/S2213-8587(18)30291-2
,2018, 'Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease', DIABETES, 67, http://dx.doi.org/10.2337/db18-258-OR
,2018, 'Cardiovascular Outcomes Reported in Hemodialysis Trials', Journal of the American College of Cardiology, 71, pp. 2802 - 2810, http://dx.doi.org/10.1016/j.jacc.2018.04.012
,2018, 'Exploring the clinical relevance of providing increased removal of large middle molecules', Clinical Journal of the American Society of Nephrology, 13, pp. 805 - 814, http://dx.doi.org/10.2215/CJN.10110917
,2018, 'FP513CARDIOVASCULAR EVENTS IN A LINKED DATA COHORT OF DIALYSIS PATIENTS: IMPACT OF MODALITY AND EVENT DEFINITION', Nephrology Dialysis Transplantation, 33, pp. i211 - i211, http://dx.doi.org/10.1093/ndt/gfy104.fp513
,2018, 'Renal trials in diabetes need a platform: time for a global approach?', The Lancet Diabetes and Endocrinology, 6, pp. 356 - 358, http://dx.doi.org/10.1016/S2213-8587(17)30263-2
,2018, 'SP243PROGNOSTIC SIGNIFICANCE OF LOW LEVEL OF BLOOD GLUCOSE IN SEVERE ACUTE KIDNEY INJURY: A SECONDARY ANALYSIS FROM THE RENAL STUDY', Nephrology Dialysis Transplantation, 33, pp. i425 - i425, http://dx.doi.org/10.1093/ndt/gfy104.sp243
,2018, 'Design and methods of the REMOVAL-HD study: A tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients', BMC Nephrology, 19, pp. 89, http://dx.doi.org/10.1186/s12882-018-0883-8
,2018, 'Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review', American Journal of Kidney Diseases, 73, pp. 332 - 343, http://dx.doi.org/10.1053/j.ajkd.2018.09.006
,2018, 'Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program', Circulation, 138, pp. 1537 - 1550, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901
,2018, 'The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics', American Journal of Nephrology, 46, pp. 462 - 472, http://dx.doi.org/10.1159/000484633
,2017, 'Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy', The Lancet, 390, pp. 1888 - 1917, http://dx.doi.org/10.1016/S0140-6736(17)30788-2
,2017, 'Action plan for optimizing the design of clinical trials in chronic kidney disease', Kidney International Supplements, 7, pp. 138 - 144, http://dx.doi.org/10.1016/j.kisu.2017.07.009
,2017, 'Closing the gap between evidence and practice in chronic kidney disease', Kidney International Supplements, 7, pp. 114 - 121, http://dx.doi.org/10.1016/j.kisu.2017.07.006
,2017, 'Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis', PLoS ONE, 12, pp. e0184398, http://dx.doi.org/10.1371/journal.pone.0184398
,2017, 'Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial', JAMA - Journal of the American Medical Association, 318, pp. 432 - 442, http://dx.doi.org/10.1001/jama.2017.9362
,2017, 'A trial of extending hemodialysis hours and quality of life', Journal of the American Society of Nephrology, 28, pp. 1898 - 1911, http://dx.doi.org/10.1681/ASN.2015111225
,2017, 'Scoring Risk Scores: Considerations Before Incorporating Clinical Risk Prediction Tools Into Your Practice', American Journal of Kidney Diseases, 69, pp. 555 - 557, http://dx.doi.org/10.1053/j.ajkd.2017.02.005
,2017, 'Identifying and integrating patient and caregiver perspectives for clinical practice guidelines on the screening and management of infectious microorganisms in hemodialysis units', Hemodialysis International, 21, pp. 213 - 223, http://dx.doi.org/10.1111/hdi.12457
,2017, 'Muscle strength, mobility, quality of life and falls in patients on maintenance haemodialysis: A prospective study', Nephrology, 22, pp. 220 - 227, http://dx.doi.org/10.1111/nep.12749
,2017, 'Canagliflozin slows progression of renal function decline independently of glycemic effects', Journal of the American Society of Nephrology, 28, pp. 368 - 375, http://dx.doi.org/10.1681/ASN.2016030278
,2017, 'Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial', Clinical Nephrology, 88, pp. 301 - 310, http://dx.doi.org/10.5414/CN109198
,2017, 'We need to talk about depression and dialysis: But what questions should we ask, and does anyone know the answers?', Clinical Journal of the American Society of Nephrology, 12, pp. 222 - 224, http://dx.doi.org/10.2215/CJN.13031216
,2016, 'Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference', Kidney International, 90, pp. 1175 - 1183, http://dx.doi.org/10.1016/j.kint.2016.09.010
,2016, 'Effects of the mediterranean diet on cardiovascular outcomes-a systematic review and meta-analysis', PLoS ONE, 11, pp. e0159252, http://dx.doi.org/10.1371/journal.pone.0159252
,